Short Description

NGS genetic DNA test detecets for variant and mutation detection in CEBPA gene for Leukemia, myeloid acute form, due to CEBPA germline mutation

PreTest Information

Clinical History of Patient who is going for CEBPA Gene Leukemia, myeloid acute form, due to CEBPA germline mutation NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CEBPA Gene Leukemia, myeloid acute form, due to CEBPA germline mutation NGS Genetic DNA Test gene CEBPA

Detail Description

CEBPA Gene Leukemia: Symptoms, Diagnosis, and Cost of NGS Genetic DNA Test

Leukemia is a type of cancer that affects the blood and bone marrow, the spongy tissue inside bones where blood cells are made. Myeloid acute leukemia is a type of leukemia that affects the white blood cells that fight infection and disease. One of the genetic mutations that can cause myeloid acute leukemia is a germline mutation in the CEBPA gene.

What is the CEBPA Gene?

The CEBPA gene provides instructions for making a protein called CCAAT/enhancer binding protein alpha. This protein is involved in the development and maturation of white blood cells, which are an important part of the immune system. Mutations in the CEBPA gene can disrupt the normal development of white blood cells and lead to myeloid acute leukemia.

Symptoms of CEBPA Gene Leukemia

The symptoms of CEBPA gene leukemia are similar to those of other types of leukemia. They can include:

• Fever or chills
• Fatigue or weakness
• Shortness of breath
• Easy bruising or bleeding
• Petechiae (tiny red spots on the skin)
• Bone pain or tenderness
• Swollen lymph nodes
• Weight loss

Diagnosis of CEBPA Gene Leukemia

Diagnosis of CEBPA gene leukemia involves a combination of tests, including:

• Complete blood count (CBC) to measure the number and types of blood cells
• Bone marrow biopsy to examine a sample of bone marrow for leukemia cells
• Cytogenetic analysis to look for changes in the chromosomes of leukemia cells
• NGS genetic DNA test to identify germline mutations in the CEBPA gene

Cost of NGS Genetic DNA Test for CEBPA Gene Leukemia

The cost of NGS genetic DNA test for CEBPA gene leukemia in India is around INR 20,000. This test uses next-generation sequencing technology to analyze the DNA of a patient and identify any mutations in the CEBPA gene that may be causing leukemia.

NGS genetic DNA test is a highly accurate and reliable test that can help doctors diagnose CEBPA gene leukemia and develop a personalized treatment plan for the patient. It is a non-invasive test that requires only a small blood sample from the patient.

Conclusion

CEBPA gene leukemia is a rare but serious type of myeloid acute leukemia that is caused by a germline mutation in the CEBPA gene. Symptoms of this condition are similar to those of other types of leukemia, and diagnosis involves a combination of tests including NGS genetic DNA testing. The cost of NGS genetic DNA test for CEBPA gene leukemia in India is around INR 20,000. This test is highly accurate and reliable and can help doctors develop a personalized treatment plan for the patient.

If you suspect that you or someone you know may have CEBPA gene leukemia, it is important to speak with a doctor as soon as possible to discuss testing and treatment options.

For more information about NGS genetic DNA testing for CEBPA gene leukemia, contact DNA Labs India.

CEBPA gene mutations are commonly associated with acute myeloid leukemia (AML), particularly in cases where these mutations occur somatically (in non-germline cells). However, it's important to clarify that CEBPA germline mutations are not a typical cause of acute myeloid leukemia. Instead, CEBPA germline mutations are more often associated with a familial predisposition to AML, which means that individuals with these mutations have an increased risk of developing AML over their lifetime.

A germline mutation refers to a mutation that is present in the individual's germ cells (sperm or egg cells) and can be passed on to their offspring. In the case of CEBPA germline mutations, there is an increased susceptibility to AML, but it's not a common cause of the disease.

Next-Generation Sequencing (NGS) genetic DNA tests can be used to analyze the DNA sequence of genes like CEBPA to identify any mutations, including germline mutations, that may be associated with a predisposition to AML.

If you or someone you know is undergoing genetic testing for CEBPA germline mutations in the context of a familial predisposition to AML, I recommend consulting with a hematologist-oncologist or a medical geneticist. They can provide you with personalized guidance on monitoring and management strategies based on the genetic profile and familial history. Keep in mind that medical knowledge can evolve, so it's important to rely on expert medical professionals for the latest information.